Navigation Links
Sanofi-aventis Enters Into Research Collaboration With Columbia University to Develop New Diabetes Treatments
Date:3/24/2011

BRIDGEWATER, N.J., March 24, 2011 /PRNewswire/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today a research collaboration with Columbia University Medical Center for the development of innovative diabetes medicines.  This three-year research collaboration, with the laboratory of Dr. Gerard Karsenty, will investigate the role of the osteoblast-secreted peptide, osteocalcin, in diabetes management.

In a landmark paper published in the research journal Cell in 2007, Dr. Karsenty, the Paul A. Marks Professor and Chair of the Department of Genetics and Development at Columbia University, and colleagues revealed that bone-forming cells called osteoblasts produce osteocalcin, a hormone that influences blood sugar levels and fat deposition.  These findings provided the first in vivo evidence of endocrine regulation of energy metabolism by the skeleton and opened the door for an entirely new area of exploration for novel pathways, targets and therapies directed toward metabolic disorders, including diabetes.

"We have spent more than a decade uncovering the biology of osteocalcin," said Dr. Karsenty, "so we are delighted to have sanofi-aventis as a collaborating partner to help us continue this research."

The collaboration will benefit from the extensive biological expertise of Dr. Karsenty and his team around osteocalcin and its role in metabolic regulation, while leveraging sanofi-aventis' long and successful experience with drug discovery and development.

"Sanofi-aventis strives to deliver innovative and integrated patient-focused solutions for people living with diabetes, and this collaboration with Columbia University is an opportunity to collaborate with leading scientists on a new approach to diabetes management," explained Dr. Paul Chew, Senior Vice President, U.S. Chief Science Officer and Chief Medical Officer, sanofi-aventis U.S.  "Sanofi-aventis is excited to work with Dr. Karsenty and his team to help translate their findings into potential new therapies that benefit patients."  

Under the collaboration, sanofi-aventis will sponsor research in Dr. Karsenty's laboratory and has an option to license and develop existing patents and results that may arise from the research into potential diabetes treatments.  Financial terms of this agreement were not disclosed.

About Diabetes
Diabetes is a chronic, widespread condition in which the body does not produce or properly use insulin, the hormone needed to transport glucose (sugar) from the blood into the cells of the body for energy. More than 230 million people worldwide are living with the disease, and this number is expected to rise to a staggering 350 million within 20 years.  It is estimated that nearly 26 million Americans have diabetes, including an estimated 7 million who remain undiagnosed.  At the same time, approximately 40 percent of those diagnosed are not achieving the blood sugar control target of A1C <7 percent recommended by the American Diabetes Association (ADA). The A1C test measures average blood glucose levels over the past two-to three-month period.

About sanofi-aventis
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone.  Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). For more information, please visit: www.sanofi-aventis.com.  

Media contact:
Elizabeth Baxter
sanofi-aventis
(908) 981-5360
elizabeth.baxter@sanofi-aventis.com

Sanofi-aventis: www.sanofi-aventis.us
Media Relations: Tel. : 908-981-6010
E-mail:  us.media-relations@sanofi-aventis.com
Investor Relations: Tel. : 908-981-5560
E-mail: IR@sanofi-aventis.com


'/>"/>
SOURCE sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
2. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
3. Sanofi-aventis Stands Behind the Safety of Lantus(R)
4. Fovea Pharmaceuticals to be Acquired by sanofi-aventis
5. Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
6. Prasco Enters into Agreements with sanofi-aventis U.S. to Provide Sales Support and Distribution Services for Authorized Generic Versions Under the Winthrop Label in U.S.
7. Sanofi-aventis Obtains Antitrust Clearance in Connection With Chattem, Inc. Tender Offer
8. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
9. Sanofi-aventis Commences Tender Offer for All Outstanding Shares of Chattem, Inc.
10. Sanofi-aventis to Acquire Chattem Inc., Creating a Strong U.S. Consumer Healthcare Platform
11. Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
Breaking Medicine Technology:
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute ... Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s newest ... world, and the most handsome men, look naturally attractive. Plastic surgery should be ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces its ... The PluriQ™ G9™ Gene Editing System is a complete system for ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, InhaleLabs.com (Inhale) offilially ... their medication by matching users with high quality water pipes within an ideal price ... commitment. , Inhale was founded by two brothers, Nick and Mike Hunter, who use ...
Breaking Medicine News(10 mins):